Abstract:Developing biocompatible, multifunctional and in-situ labeling nanoplatform is high challenging for molecular imaging. Organic derivates melanin nanoparticles (MNPs) holds great potential to be multimodal contrast agents, and have been used for photoacoustic imaging, magnetic resonance imaging, and Cu-64 PET imaging with simple modifications. In order to extend MNPs application in molecular imaging, here a novel radio-nuclide was applied to in-situ labeling of MNPs. Large numbers of active dihydroxyindole/indolequinone groups and natural binding ability of MNPs enabled them to have the ability to label different types of radionuclides which have unique half-life and functions, especially long-life elemental nuclide. This project explored the in-situ labeling methods of organic melanin nanoparticles with a promising diagnostic radionuclides named Iodine-124 (I-124), and using this novel multifunctional organic nanoparticles for preliminary molecular imaging studies. Generally, ultrafine particle size melanin nanoparticles (5.5 nm in diameter) were prepared by ultrasonication method using naturally occurring melanin, then PEG(3500) which had amino group at both ends was used as a stabilizer agent to obtain PEG-MNP nanocarriers (7.5 nm in diameter) with better water solubility and stability. The nanoparticles were full characterized by dynamic light scattering (DLS), transmission electron microscope (TEM) and H-1 NMR, respectively. Then, one kind of elemental nuclide was labeled. Classic iodine labeled method with N-Bromo Succinimide (NBS) was used as oxidant to oxidize active dihydroxyindole/indolequinone ring of PEG-MNP for electrophilic substitution reaction labeling I-124 (100.8 h). This reaction rate is extremely fast (60 s reaction time) and high labelling yield (>99%). The I-124 was labeled successfully and in-situ labeled PEG-MNP nanocarriers were obtained. After that, I-124 and I-124-PEG-MNP were used to further preclinical evaluation by micro-PET imaging. Micro-PET images were collected at 2 h, 24 h and 48 h after intravenous injection 7.4 MBq I-124 and I-124-PEG-MNP in normal Kunming mice (n=3). The ROI target area of heart, liver and thyroid were delineated for semi-quantitative analysis. Then, in order to verify the imaging ability of I-124-PEG-MNP in solid tumor. We built human pancreatic cancer BxPC3 xenograft model (n=3), and Micro-PET scans were performed at different time points. Results showed that the labeling rate of I-124 on PEG-MNP was 99.9%. And the radiochemical purity in vitro stability of I-124-PEG-MNP in 96 h was more than 90%. Micro-PET images showed that I-124-PEG-MNP had no obvious thyroid uptake which indicated no de-marking in mice. The radio-distribution of I-124 and I-124-PEG-MNP was substantially different in liver and thyroid (P<0.001). In vivo semi-quantitative analysis showed that the radio uptakes of organs were consistent with the distribution of nanoparticles. And the PET imaging of xenograft mice showed that I-124-PEG-MNP can utilize the enhanced permeability and retention effect (EPR) to be significantly enriched at the tumor and retained in the tumor site for more than 48 h. PEG-MNP has the ability to label long half-life nuclide I-124. This research provides an experimental basis for further construction of long-circulation multimodal imaging probes.

Synthesis and evaluation of 18F-labeled procainamide as a PET imaging agent for malignant melanoma

Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice.

The synthesis of a novel molecular imaging probe 68Ga-DOTA-PDL1P and application in mouse model of melanoma

Development of Radiofluorinated Nicotinamide/Picolinamide Derivatives as Diagnostic Probes for the Detection of Melanoma

Imaging a Pancreatic Carcinoma Xenograft Model with 11C-Acetate: a Comparison Study with 18F-FDG

64Cu-labeled melanin nanoparticles for PET/CT and radionuclide therapy of tumor.

Melanin-targeted [18F]-PFPN PET imaging may shed light for clear cell sarcoma

Application of 68Ga-Psma-617 Molecular Probe for Micro-PET Imaging of Gliomas Model

Synthesis and Evaluation of F-18-Ambf3-Psma Derivatives As Pet Imaging Agents for Prostate Cancer

Preclinical ImmunoPET Imaging Using a Zr-89-Labeled Anti-CD146 Monoclonal Antibody for Diagnosis of Melanoma.

In vivo studies of Gd-DTPA-monoclonal antibody and gd-porphyrins: potential magnetic resonance imaging contrast agents for melanoma

The imaging study of a small-molecular inhibitor targeting prostate speciifc membrane antigen

Preliminary Study of Radionuclide-Labeled MerTK-Targeting PET Imaging Agents for the Diagnosis of Melanoma

Preparation and Preliminary Molecular Imaging Study of 124I In-Situ Labeled Organic Melanin Nanoparticles

A novel PSMA targeted dual-function near-infrared fluorescence and PET probe for the image-guided surgery and detection of prostate cancer

Apoptosis Imaging Probe Predicts Early Chemotherapy Response In Preclinical Models: A Comparative Study With F-18-Fdg Pet

Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging

Development of [18F]DASA-23 for Imaging Tumor Glycolysis Through Noninvasive Measurement of Pyruvate Kinase M2

Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen

Melanin-Targeted PET Imaging Sheds Light on Pigment Epithelioma in Corpus Ciliare

Neuromelanin-targeted 18 F-P3BZA PET/MR imaging of the substantia nigra in rhesus macaques